CAR-T challenges patent rules

There are three CAR-T Cell treatments approved by the TGA and two that are reimbursed by the federal government, yet concerns are raised that Australia's patent system may not be adequate for the new technology.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here